Ramharack R, Barkalow D, Spahr M A
Department of Vascular and Cardiac Diseases, Parke-Davis Pharmaceutical Research, Warner-Lambert Co, Ann Arbor, Mich 48105, USA.
Arterioscler Thromb Vasc Biol. 1998 Jun;18(6):984-90. doi: 10.1161/01.atv.18.6.984.
Lipoprotein(a) [Lp(a)] consists of apolipoprotein(a) [apo(a)] disulfide linked to apolipoprotein B-100 of LDL. Elevated plasma Lp(a) is an independent risk factor for a variety of vascular diseases. Lp(a) has been reported to be an acute-phase reactant, suggesting that cytokines may regulate its levels. To determine whether Lp(a) expression was subject to modulation by cytokines, primary monkey hepatocytes that endogenously express Lp(a) were used. Hepatocytes were treated with interleukin (IL)-6, the major mediator of the acute-phase response, and several other cytokines. IL-6 treatment (0.3 to 10 ng/mL) resulted in a marked, dose-dependent, 2- to 4-fold enhancement of Lp(a) accumulation in the hepatocyte culture media that was highly correlated with changes in apo(a) mRNA levels (r>0.9). Several other cytokines, such as IL-2, IL-8, and hepatocyte growth factor, had no significant effect on Lp(a) levels; however, transforming growth factor-beta1 (TGF-beta1) and tumor necrosis factor-alpha (TNF-alpha) were very active in inhibiting Lp(a) accumulation in the culture media, with IC50s of approximately 0.3 and 1 ng/mL, respectively. Both TGF-beta1 and TNF-alpha also decreased the apo(a) transcript. Mixing experiments, in which hepatocytes were treated with 10 ng/mL of IL-6 and 0.3 to 10 ng/mL of TGF-beta1 or TNF-alpha, demonstrated that the IL-6-mediated induction of Lp(a) and apo(a) mRNA was ablated with very low levels of either inhibitory cytokine, suggesting a dominant negative effect of TGF-beta1 and TNF-alpha. These results show that Lp(a) and apo(a) mRNA expression in primary monkey hepatocytes is subject to both positive (IL-6) and negative (TGF-beta1 and TNF-alpha) regulation by physiological levels of cytokines. Thus, in vivo Lp(a) levels may be dependent on the balance between stimulatory and inhibitory cytokines.
脂蛋白(a)[Lp(a)]由通过二硫键与低密度脂蛋白(LDL)的载脂蛋白B-100相连的载脂蛋白(a)[apo(a)]组成。血浆Lp(a)升高是多种血管疾病的独立危险因素。据报道,Lp(a)是一种急性期反应物,提示细胞因子可能调节其水平。为了确定Lp(a)的表达是否受细胞因子调节,使用了内源性表达Lp(a)的原代猴肝细胞。用急性期反应的主要介质白细胞介素(IL)-6和其他几种细胞因子处理肝细胞。IL-6处理(0.3至10 ng/mL)导致肝细胞培养基中Lp(a)积累显著、剂量依赖性地增强2至4倍,这与apo(a) mRNA水平的变化高度相关(r>0.9)。其他几种细胞因子,如IL-2、IL-8和肝细胞生长因子,对Lp(a)水平无显著影响;然而,转化生长因子-β1(TGF-β1)和肿瘤坏死因子-α(TNF-α)在抑制培养基中Lp(a)积累方面非常活跃,IC50分别约为0.3和1 ng/mL。TGF-β1和TNF-α也降低了apo(a)转录本。混合实验中,用10 ng/mL的IL-6以及0.3至10 ng/mL的TGF-β1或TNF-α处理肝细胞,结果表明,极低水平的任何一种抑制性细胞因子都会消除IL-6介导的Lp(a)和apo(a) mRNA的诱导,提示TGF-β1和TNF-α具有显性负效应。这些结果表明,原代猴肝细胞中Lp(a)和apo(a) mRNA的表达受细胞因子生理水平的正向(IL-6)和负向(TGF-β1和TNF-α)调节。因此,体内Lp(a)水平可能取决于刺激性和抑制性细胞因子之间的平衡。